Related Experiment Video
Updated: Dec 1, 2025
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
In-Stent Restenosis and a Drug-Coated Balloon: Insights from a Clinical Therapeutic Strategy on Coronary Artery
Dai-Min Zhang1, Shaoliang Chen1
1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China.
Insights
Drug-coated balloons show promise for treating in-stent restenosis after coronary artery procedures. This approach offers an effective alternative for managing restenosis, a complication of drug-eluting stents.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Background:
- Coronary heart disease is a leading cause of mortality and morbidity.
- Stent implantation is a common treatment for coronary artery lesions.
- In-stent restenosis (ISR) remains a significant complication of drug-eluting stents, leading to adverse cardiovascular events.
Purpose of the Study:
- To review advancements in coronary intervention.
- To highlight the clinical efficacy of drug-coated balloons (DCB) for treating ISR.
- To provide insights into current treatment challenges for ISR.
Main Methods:
- Literature review of coronary intervention techniques.
- Analysis of studies evaluating drug-coated balloons for ISR treatment.
- Comparison of DCB efficacy with existing treatments like drug-eluting stents.
Main Results:
- Drug-eluting stents have a restenosis rate of 10%-20%.
- In-stent restenosis can cause recurrent angina, myocardial infarction, and sudden cardiac death.
- Drug-coated balloons demonstrate promising clinical efficacy comparable to drug-eluting stents in managing ISR.
Conclusions:
- Drug-coated balloons represent a viable and effective option for treating in-stent restenosis.
- Further research and clinical adoption of DCBs can improve outcomes for patients with coronary artery disease.
- DCBs offer a potential solution to the challenges posed by ISR after stenting.
Abstract:
Coronary heart disease is a major cause of death and disability in developed countries. Stent implantation has become an efficacious treatment for a culprit lesion vessel of the coronary artery. However, 10%-20% restenosis is still an important complication that restricts the clinical safety and efficacy of drug-eluting stents. In-stent restenosis may lead to the recurrence of major cardiovascular adverse events, including angina pectoris, acute myocardial infarction, and even sudden cardiac death. These events are currently serious problems that occur after coronary stent implantation. Clinical physicians face a difficult choice for in-stent restenosis treatment. Recent studies indicate that a drug-coated balloon has promising clinical efficacy similar to the drug-eluting stents for treating coronary in-stent restenosis. Therefore, in this study, we highlight the progress of coronary intervention and the use of drug-coated balloons in the treatment of in-stent restenosis (ISR).
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Atherosclerosis III: Management
01:26Angina IV: Management
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:28Acute Coronary Syndrome IV: Interprofessional Care